Its ability to modulate p53 activity in cancer cells that retain TP53-WT, together with its chemoprotective effects in normal tissues, makes ALRN-6924 a valuable candidate for both solid and hematological malignancies. This evidence concerns the gene TP53 and hematologic disorder.